Loading [MathJax]/extensions/tex2jax.js

Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Autoren

  • Firat Baris Barlas
  • Bilge Olceroglu
  • Didem Ag Seleci
  • Zinar Pinar Gumus
  • Frank Stahl
  • Thomas Scheper

Organisationseinheiten

Externe Organisationen

  • İstanbul Üniversitesi - Cerrahpaşa
  • Technische Universität Braunschweig
  • Ege University
  • Bahcesehir University

Details

OriginalspracheEnglisch
Aufsatznummere70079
Seitenumfang10
FachzeitschriftCancer medicine
Jahrgang13
Ausgabenummer15
PublikationsstatusVeröffentlicht - 9 Aug. 2024

Abstract

Background: Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective: This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. Methods: The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. Results: The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297). Conclusion: The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer. / Barlas, Firat Baris; Olceroglu, Bilge; Ag Seleci, Didem et al.
in: Cancer medicine, Jahrgang 13, Nr. 15, e70079, 09.08.2024.

Publikation: Beitrag in FachzeitschriftArtikelForschungPeer-Review

Barlas, FB, Olceroglu, B, Ag Seleci, D, Gumus, ZP, Siyah, P, Dabbek, M, Garnweitne, G, Stahl, F, Scheper, T & Timur, S 2024, 'Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer', Cancer medicine, Jg. 13, Nr. 15, e70079. https://doi.org/10.1002/cam4.70079
Barlas, F. B., Olceroglu, B., Ag Seleci, D., Gumus, Z. P., Siyah, P., Dabbek, M., Garnweitne, G., Stahl, F., Scheper, T., & Timur, S. (2024). Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer. Cancer medicine, 13(15), Artikel e70079. https://doi.org/10.1002/cam4.70079
Barlas FB, Olceroglu B, Ag Seleci D, Gumus ZP, Siyah P, Dabbek M et al. Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer. Cancer medicine. 2024 Aug 9;13(15):e70079. doi: 10.1002/cam4.70079
Barlas, Firat Baris ; Olceroglu, Bilge ; Ag Seleci, Didem et al. / Enhancing chemotherapeutic efficacy : Niosome-encapsulated Dox-Cis with MUC-1 aptamer. in: Cancer medicine. 2024 ; Jahrgang 13, Nr. 15.
Download
@article{79b149190e484dbfa5382b70125778bc,
title = "Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer",
abstract = "Background: Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective: This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. Methods: The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. Results: The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297). Conclusion: The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.",
keywords = "cisplatin, combine drug, doxorubicin, MUC-1, niosome",
author = "Barlas, {Firat Baris} and Bilge Olceroglu and Didem Ag Seleci and Gumus, {Zinar Pinar} and Pinar Siyah and Meriam Dabbek and Georg Garnweitne and Frank Stahl and Thomas Scheper and Suna Timur",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2024",
month = aug,
day = "9",
doi = "10.1002/cam4.70079",
language = "English",
volume = "13",
journal = "Cancer medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "15",

}

Download

TY - JOUR

T1 - Enhancing chemotherapeutic efficacy

T2 - Niosome-encapsulated Dox-Cis with MUC-1 aptamer

AU - Barlas, Firat Baris

AU - Olceroglu, Bilge

AU - Ag Seleci, Didem

AU - Gumus, Zinar Pinar

AU - Siyah, Pinar

AU - Dabbek, Meriam

AU - Garnweitne, Georg

AU - Stahl, Frank

AU - Scheper, Thomas

AU - Timur, Suna

N1 - Publisher Copyright: © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2024/8/9

Y1 - 2024/8/9

N2 - Background: Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective: This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. Methods: The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. Results: The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297). Conclusion: The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.

AB - Background: Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective: This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. Methods: The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. Results: The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 ± 1.407) than on U87 cells (46.653 ± 1.297). Conclusion: The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.

KW - cisplatin

KW - combine drug

KW - doxorubicin

KW - MUC-1

KW - niosome

UR - http://www.scopus.com/inward/record.url?scp=85200903275&partnerID=8YFLogxK

U2 - 10.1002/cam4.70079

DO - 10.1002/cam4.70079

M3 - Article

C2 - 39118454

AN - SCOPUS:85200903275

VL - 13

JO - Cancer medicine

JF - Cancer medicine

SN - 2045-7634

IS - 15

M1 - e70079

ER -

Von denselben Autoren